Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics

Authors

  • Anthony J. Hickey,

    Corresponding author
    1. Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360
    • Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360. Telephone: (919) 962-0223; Fax: (919) 966-0197.
    Search for more papers by this author
  • Heidi M. Mansour,

    1. Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360
    Search for more papers by this author
  • Martin J. Telko,

    1. Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360
    Search for more papers by this author
  • Zhen Xu,

    1. Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360
    Search for more papers by this author
  • Hugh D.C. Smyth,

    1. Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Campus Box #7360, 1310 Kerr Hall, Kerr Hall, Chapel Hill, North Carolina 27599-7360
    Current affiliation:
    1. Currently, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131.
    Search for more papers by this author
  • Tako Mulder,

    1. DMV-Fonterra Excipients, Goch, Germany
    Search for more papers by this author
  • Richard McLean,

    1. Pfizer Inc., Sandwich, Kent, UK
    Search for more papers by this author
  • John Langridge,

    1. DMV-Fonterra Excipients, Goch, Germany
    Search for more papers by this author
  • Dimitris Papadopoulos

    1. Pfizer Inc., Sandwich, Kent, UK
    Search for more papers by this author

Abstract

The performance of dry powder aerosols for the delivery of drugs to the lungs has been studied extensively in the last decade. The focus for different research groups has been on aspects of the powder formulation, which relate to solid state, surface and interfacial chemistry, bulk properties (static and dynamic) and measures of performance. The nature of studies in this field, tend to be complex and correlations between specific properties and performance seem to be rare. Consequently, the adoption of formulation approaches that on a predictive basis lead to desirable performance has been an elusive goal but one that many agree is worth striving towards. The purpose of this paper is to initiate a discussion of the use of a variety of techniques to elucidate dry particle behavior that might guide the data collection process. If the many researchers in this field can agree on this, or an alternative, guide then a database can be constructed that would allow predictive models to be developed. This is the first of two papers that discuss static and dynamic methods of characterizing dry powder inhaler formulations. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 1282–1301, 2007

Ancillary